Crossmark

Cost Effectiveness of Inhaled Mannitol (Bronchitol®) in Patients with Cystic Fibrosis

Crossref DOI link: https://doi.org/10.1007/s40273-019-00767-8

Published Online: 2019-01-22

Published Print: 2019-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Warren, Emma https://orcid.org/0000-0002-8866-421X
Morgan, Kristen

Toward, Toby J.

Schwenkglenks, Matthias

Leadbetter, Joanna
Funding

Funding for this research was provided by:

Pharmaxis Ltd (NA)
License Information

Text and Data Mining valid from 2019-01-22
More Information

Article History

First Online: 22 January 2019

Compliance with Ethical Standards

:

: This article/research was funded by Pharmaxis Ltd.

: Emma Warren and Toby Toward have received consulting fees from Pharmaxis Ltd. Matthias Schwenkglenks has received research funding via an employment institution from Pharmaxis Ltd. Joanna Leadbetter and Kristen Morgan are employees of Pharmaxis Ltd.

: Several datasets were used for this analysis (CF-301/CF-302). The patient-level data are not publicly available, but the results of the trials have been presented in several publications. Model inputs are described within the article. The model was developed in TreeAge Pro 2017, and is not publicly available, but is available from the authors upon reasonable request, with authorisation from Pharmaxis Ltd. and receipt of a signed confidentially agreement.